Clinical trials: Stereotactic Body Radiation Therapy
Prostate Cancer
MICRO-ultrasound Guided Prostate SBRT
This study will test whether it is safe and effective to use stereotactic body radiation therapy (SBRT)-a short, targeted form of radiation-together with a microultrasound (microUS)-guided radiation boost to the cancerous spots…
- Trial name
- MICRO-S (NCT07737457)
- Testing
- Stereotactic Body Radiation Therapy, ExactVu
- Where
- Canada
- Volunteers
- 112 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
HCC - Hepatocellular Carcinoma, Tremelimumab
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, Radiotherapy
- Trial name
- Photon-STRIDE (NCT06999707)
- Testing
- Photon radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Neoplasm Metastasis, Neoplastic Processes
Fractionated Radiosurgery for Painful Spinal Metastases
It is the study hypothesis that hypo-fractionated image-guided radiosurgery significantly improves pain relief compared to historic data of conventionally fractionated radiotherapy.
- Conditions
- Neoplasm Metastasis, Neoplastic Processes, Neoplasm Recurrence, Local, Neoplasm, Residual
- Trial name
- DOSIS (NCT01594892)
- Testing
- Radiosurgery
- Where
- 5 sites in Germany, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Wuerzburg University Hospital
Pancreatic Cancer
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
The goal of this study is to determine the safety and efficacy of a chemotherapy regimen known as Modified FOLFIRINOX (mFFX) alone or with the addition of Stereotactic Body Radiotherapy (SBRT).
- Trial name
- NCT01926197
- Testing
- Oxaliplatin, Irinotecan, Leucovorin
- Where
- 9 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Stanford University
NSCLC, Stage I
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)
This is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC.
- Trial name
- ASTEROID (NCT03446547)
- Testing
- Durvalumab
- Where
- 15 sites in Finland, Norway and 1 more
- Volunteers
- 106 people
- Sponsor
- Vastra Gotaland Region
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
The aim of this study is to evaluate the efficacy of 2 cycles of combinatory adebrelimab and stereotactic radiotherapy, followed by monotherapy adebrelimab in patients with metastatic castration-resistant prostate cancer. Dr.
- Trial name
- NCT06251492
- Testing
- Stereotactic body radiotherapy, Adebrelimab
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Breast Carcinoma, Colorectal Carcinoma
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
This phase I trial studies the side effects and best dose of M5A-IL2 immunocytokine (M5A-ICK) combined with stereotactic body radiation therapy (SBRT) and to see how well they work in treating patients with colorectal cancer or…
- Trial name
- NCT06130826
- Testing
- Biopsy, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Metastatic Castration-resistant Prostate Cancer
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior…
- Trial name
- PORTER (NCT03835533)
- Testing
- NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B)
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Parker Institute for Cancer Immunotherapy
Glottic Carcinoma
Volumetric Adaptive SBRT Versus Conventional Accelerated Radiation Therapy for Early-Stage Glottic Cancer
This non-inferiority trial will compare conventional long-course accelerated fractionation radiation therapy (AF-RT) with volumetric adaptive stereotactic body radiation therapy (SBRT) in patients with early-stage (cT1-2N0M0)…
- Trial name
- VOICE (NCT07895745)
- Testing
- Long course accelerated fractionation radiation therapy, Adaptive stereotactic body radiation therapy
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University Health Network, Toronto
Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
This study will implement a new treatment regimen for patients with advanced and inoperable pancreatic cancer using chemotherapy combinations of Folfirinox or gemcitabine-nab paclitaxel (abraxane) followed by a short course of…
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer
- Trial name
- NCT03600623
- Testing
- Folfirinox, Gemcitabine nab-Paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy…
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Non-Metastatic
- Trial name
- ABRUPT 2 (NCT07407608)
- Testing
- SBRT, SDRT
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Milano Bicocca
Low or Intermediate Risk Prostate Cancer
Phase I Study MR-guided SBRT to PCa
1) investigate the feasibility, tolerance, and safety of dose escalation via MR-guided stereotactic body radiation therapy and simultaneous integrated boost to the dominant intraprostatic lesions (DILs), 2) to assess the…
- Trial name
- MRgRTPCa (NCT03935308)
- Testing
- MR guided Linear Accelerator
- Where
- United States
- Sponsor
- Henry Ford Health System
Prostate CA
Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer
Prostate cancer is a common cancer, and a significant cause of cancer death in men. There are many potentially curative treatment options for prostate cancers that have not spread.
- Trial name
- ADAPT-25 (NCT06835725)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Non-small Cell Lung Cancer
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer
A new type of treatment called stereotactic radiotherapy has recently been developed in hopes of improving the success of the treatment and improving the convenience to patients, while reducing the side effects.
- Trial name
- NCT00888823
- Testing
- Stereotactic Radiotherapy
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
Radiotherapy, Spine Metastases
Stereotactic Radiotherapy and Image-guided Intensity Modulated Radiotherapy for Spinal Metastatic Tumors
Data of 100 patients with spinal metastatic tumor who received stereotactic radiotherapy or conventionally-fractionated image-guided intensity-modulated radiotherapy in the multi-center of the research group from July 2019 to…
- Conditions
- Radiotherapy, Spine Metastases, Radiosurgery
- Trial name
- SCIRSM (NCT03963713)
- Testing
- Stereotactic radiotherapy, Conventionally-fractionated image- guided Intensity modulated radiotherapy
- Where
- 10 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Pancreatic Cancer, Adenocarcinoma
Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer
The purpose of this study is to determine whether a short-course of stereotactic body radiotherapy (SBRT) prior to surgical resection of pancreatic adenocarcinoma is feasible and well-tolerated.
- Trial name
- NCT02347618
- Testing
- Preoperative SBRT
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Rochester
Non-Small Cell Lung Carcinoma (NSCLC)
ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety and effectiveness of Iressa when used with a short course of high dose radiation therapy in patients with lung cancer.
- Trial name
- NCT00328562
- Testing
- ZD1839 (Iressa), Thoracic Radiotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Advanced Solid Tumors
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The goal of this clinical trial is to assess the safety and tolerability of AT1019 when used in combination with SBRT and PD-1 inhibitor, and determine the maximum tolerated dose (MTD) of AT1019 in the combination therapy of SBRT…
- Trial name
- NCT07285395
- Testing
- AT1019
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Metastatic Castrate-resistant Prostate Cancer, mCRPC
Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide…
- Trial name
- NCT01818986
- Testing
- Sipuleucel-T, Stereotactic Ablative Body Radiation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Prostate PMSABR Study
In this study, the investigator aim to evaluate the role of PMSA-PET guided SABR on progression free survival (PFS) in patients with oligoprogressive mCRPC with Enzalutamide.
- Trial name
- NCT04742972
- Testing
- SABR, SOC
- Sponsor
- Darren Poon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.